Osteoporosis Flashcards

1
Q

Osteoporosis

A

-disease characterized by low bone mass (density) & michroarchitectural deterioration leading to bone fragility & increased risk of dx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prevalence of Osteoporosis

A

-most common bone disorder
-risk of hip fx doubles q5-6y incre in age from ages 65-85yo
-affecting 10M Americans; 8M are women
-1 in 2 women aged 50yo+ will sustain osteoporosis-related dx in their life
-prior low-trauma fx (fragility fx) is also a dx of osteoporosis regardless of DEXA; excludes fingers, toes, face, skull, or pathological or traumatic fxs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Postmeno Osteoporosis

A

-peak bone mass in most women reached at age 20yo
-genetic factors account for 50-85% of variance in bone BMD; lifestyle factors like nutrition & exercise contribute less
-accelerated bone loss at spine (largely comprised of trabecular bone) a/w menopause
-by age 80yo, women have lost about 30% of their peak bone mass

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

WHO definition of BMD

A

Normal: T-score >/= -1.0
Low Bone mass (osteopenia): T-score >/= -1.0 & -2.5
Osteoporosis: T-score </= -2.5
-based on white postmeno women
-T-scores only to be used for postmeno women
-Z-scores report BMD for similar age, sex, race premeno women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Osteoporosis: Ethnic Differences

A

-BMD differences exist btwn ethnicities
-black women have higher BMD than white & hispanic (independent of body wt)
-Asian descent have lower BMD than whites, but body wt may attenuate these differences
-white & hispanic women have highest rates of osteoporosis-related fx, black women having lowest rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Osteoporosis management

A

-identify postmeno at risk for fx using DEXA & FRAX (online validated fx risk prediction tool)
-review fam hx of osteo/fxs
-dietary & lifestyle changes (smoking cessation, fall reduction, dietary ca+ intake)
-lab work up for secondary causes of osteo
-patients w osteo (by DEXA) or hx of low-trauma fx or high risk fx based on FRAX, rec for FDA-approved pharmacotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

RF captured in FRAX

A

-age
-sex
-weight & height (BMI)
-prior fragility dx
-parental hx of hip fx
-secondary causes of osteoporosis (DM type 1, vitamin D deficiency, malabsorption disorders, chronic inflammatory diseases, certain meds that affect bone loss)
-low femoral neck BMD (optional; FRAX valid wo BMD)
-RA
-current smoking
-etoh use >3units/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Bone Health H&P

A

-assess lifestyle behaviors (exercise v sedentary)
-review medical, surgical, medications
-review ca+, vit D intake
-assess annually or when physical/mental status changes occur:
>height
>if >1.4in height loss from adult peak or 0.8 in prospective loss, refer for lateral spine imaging or vertebral dx assessment
>wt
>chronic back pain or kyphosis
>RF for bone loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BMD testing recs

A

-all women >65yo
-postmeno aged <65yo if FRAX score for 10yr risk of major dx is >8.4% (avg fx risk for healthy 65yo)
-women postmeno or meno transition at high risk for fx based on clinical RF (low body wt <21 BMI, prior fx, high-risk med use, disease or condition a/w bone less)
-postmeno w hx of fragility fx
-anyone being considered for pharmacotherapy
-anyone treated, to monitor tx effect
-anyone receiving therapy in whom evidence of bone loss would lead to tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Screening Techniques

A

-choose the lowest of 3 BMD scores: total hip, femoral neck, AP lumbar (must have at least 2 vertebrae)
-trabecular bone score: provides 2D grayscale image of spine microarchitecture, independently predicted fx risk, computer software available on select DEXA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Role of Bone Turnover Markers

A

-should not be used in clinical practice
-if needed, use of serum CTX (C-terminal of type 1 collagen via a fasting morning blood sample) may help monitor med compliance or evaluate appropriate bone turnover response during permitted “drug holidays”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Confirming Vertebral Fx

A

-measure pts >50yo on wall-mounted stadiometer yearly, check for postural changes, evaluate for back pain
-suspect vertebral fx in pt w height loss regardless of back pain; >1.5in from peak, or >0.8in from last height
-radiologic confirmation
-20% vertebral height loss (4mm heigh loss from baseline)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Identify Secondary Causes

A

-hyperthyroidism, hypercalciuria, certain drugs (AIs), calcium/vitamin D deficiency, RA, celiac disease, malabsorption diseases like Crohn’s, ulcerative colitis
-secondary work up includes lab & urine tests such as CBC, CMP, LFTs, phosphorus, TSH, parathyroid hormone, 24-hr urine calcium/creatinine collection: also serum protein electrophoresis, celiac panel, 24-hr urine cortisol, other specialized tests

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lifestyle Modifications

A

-maintain healthy weight
-obtain adequate vit D (600-800IU/d) & ca+ (1200mg/d); treat vit D def w higher dose
-participate in wt-bearing, resistance/wt-training, & balance/posture exercise
-avoid excessive etoh consumption (7-10 standard drinks/wk)
-do not smoke
-institute measure for falls prevention
-evaluate meds for AEs that block ca+ absorption (PPIs) or incr risk of falls (somnolence, dizziness)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drug Therapy Indications

A

-hx of vertebral, hip, fragility, or low-trauma fx
-BMD values c/w osteoporosis
-10yr FRAX risk of major osteoporotic fx >20% or hip fx >3%
-in women on high-risk meds such as AIs or chronic glucocorticoids to prevent bone loss caused by those meds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Selecting Specific Therapy

A

-depends on AE & regimens
-classify risk of fx (moderate risk vs high risk)
-adherence to therapy is poor
-rare risks (such as osteo necrosis of jaw & atypical femoral fx) have been reported w long-term use of antiresorptives

17
Q

Individualize Tx

A

-antiresportives:
>HT (EPT)
>estrogen agonist/antagonist (raloxifene / tamoxifen)
>tissue-selective estrogen complex (CE plus bazedoxifene)
>biphosphonates (oral or IV)
>denosumab (subq)
-osteoanabolics
>teriparatide (PTH-34)
>abaloparatide (PTH-P)
-dual anabolic/antiresorptive
-romosozumab

18
Q
A